45 results
Page 2 of 3
F-1/A
tzih8syz9
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
hif748p05d4v 67
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
EX-99.1
sl3o7fwc7
28 Feb 20
Current report (foreign)
9:46am
6-K
EX-99.1
v9towud fb4bh2uo
19 Feb 20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
9:32am
F-1
qbd9p1avipmn8d
18 Feb 20
Registration statement (foreign)
5:15pm
6-K
EX-99.1
88am9wguh2u ld0xr
12 Feb 20
Mereo Biopharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
9:48am
6-K
EX-99.1
yahlofm f0m
10 Feb 20
Current report (foreign)
7:20am
6-K
EX-99.1
g9mk ivqpei8ve4o8h
14 Jan 20
Current report (foreign)
8:40am
6-K
EX-99.1
720nd8v
13 Jan 20
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
8:26am
6-K
EX-99.1
u0mpsrfxthf
22 Nov 19
Current report (foreign)
9:29am
6-K
EX-99.1
4a79zlrzvauq
7 Oct 19
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
12:23pm
6-K
EX-99.1
xtt0fky2450 n55u0
17 Sep 19
Current report (foreign)
8:06am
6-K
lxlbn c47r
17 Sep 19
Current report (foreign)
8:06am
20-F
96p 7xoaz
29 Apr 19
Annual report (foreign)
4:59pm
6-K
g2no b8kocq
29 Apr 19
Current report (foreign)
12:09pm
424B3
8i10mmicpeccg93wnbj
20 Mar 19
Prospectus supplement
4:58pm
F-4/A
hstk ttz9k2w5vk
15 Mar 19
Registration of securities (foreign) (amended)
5:08pm
425
t2zpo4x4er
12 Mar 19
Business combination disclosure
9:27am
425
71qttp
15 Feb 19
Business combination disclosure
6:50am
425
gvv5zos265q0a7nhq0p7
12 Feb 19
Business combination disclosure
12:00am